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Purpose: Outcome with selective or systematic stenting with the Palmaz vascular stent was compared in patients with
limb-threatening ischemia or persistent disabling claudication despite medical therapy, with less than 7 cm stenosis or
occlusion of the superficial femoral artery.
Methods: This was a multicenter prospective randomized trial with centralized allocation of treatment and independent
review of vascular events. The primary end point was presence of more than 50% stenosis at 1-year angiographic
follow-up. Secondary end points were survival; occurrence of vascular events in the treated leg; and number of failed
procedures, defined as more than 50% stenosis or death at 1 year.
Results: Two hundred twenty-seven patients were enrolled in the study, 112 in the selective stent group, and 115 in the
systematic stent group. Seventeen patients (15%) in the selective stent group received a stent after suboptimal results of
percutaneous transluminal angioplasty. Angiograms for 140 patients were available at 1-year follow-up and demon-
strated no statistical difference between the two groups; more than 50% stenosis of the dilated site was noted in 21 of 65
patients (32,3%) in the selective stent group and 26 of 75 patients (34.7%) in the systematic stent group (P  .85, Fisher
exact test). Survival in the percutaneous transluminal angioplasty and stent groups was, respectively, 92% and 96% at 1
year, 89% and 93% at 2 years, and 82% and 80% at 4 years (P  .40, log-rank test). Survival free of new vascular events
in the treated limb was 77% and 65% at 1 year, 70% and 53% at 2 years, and 57% and 44% at 4 years (P  .017, log-rank
test). Number of failed procedures at 1 year was 29 of 86 (33%) and 30 of 89 (34%) (P  0.9).
Conclusion: Systematic stenting of short stenosis or occlusion of the superficial femoral artery is not justified. Palmaz
vascular stent placement should be reserved for use in patients with suboptimal results of balloon angioplasty. (J Vasc
Surg 2003;37:487-94.)
Percutaneous transluminal angioplasty (PTA) is com-
monly the initial treatment option in patients with limb-
threatening ischemia or persistent disabling claudication
despite medical therapy, with relatively short lesions, of the
superficial femoral artery.
The long-term patency rate with PTA alone, however,
remains relatively poor, varying from 40% to 71% at 2 years.
Meta-analysis of 12 series of patients demonstrated 3-year
patency rates of 62%  9% for claudication and 43%  7%
for limb salvage.1 Factors that may adversely affect outcome
include symptom (claudication vs critical ischemia), type of
lesion (stenosis vs occlusion), length of lesion, and out-
flow.2-6
Stents have been designed to improve the technical
success rate and overall arterial patency after PTA. By fixing
the plaque against the arterial wall, stents prevent immedi-
ate recoil and obstructive plaque dissection. However,
there is a tendency for development of intrastent hyperpla-
sia, which may compromise long-term results.
Early studies demonstrated effective results with stent-
ing in the superficial femoral artery.7-11,12 Limits of stent-
ing were also delineated, with the poorest results obtained
in patients with long lesions or with critical ischemia.13,14
Three randomized studies15-17 comparing PTA alone
versus PTA plus stent placement in the superficial artery all
failed to demonstrate a benefit to stenting insofar as long-
term patency and symptom relief. However these studies
included a relatively small number of patients, with short
follow-up.
The current prospective randomized study was under-
taken before the results of the above-mentioned studies
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were available. The purpose of the study was to compare
results of systematic or selective stenting of the superficial
femoral artery after balloon angioplasty in patients with
lesions smaller than 7 cm and disabling claudication or
lower limb critical ischemia. Special emphasis was placed on
patency at 1 year, as demonstrated on a control angiogram,
and to occurrence of ischemic events in the ipsilateral leg
during 4 years of follow-up.
METHODS
Between June 1995 and December 1997, 227 patients
who had undergone superficial femoral angioplasty were
randomly allocated to undergo balloon angioplasty plus
systematic stenting, PTA alone, or PTA plus stenting,
because of suboptimal results of PTA.
All patients were informed of the purpose of the study
and signed an informed consent. The protocol was ap-
proved by the ethics committee of Henri Mondor Hospital,
Cre´teil, France, on Jan 16, 1995. The study was carried out
in accord with the Hurriet regulation, which defines the
rules for scientific protocols in France, and with good
clinical practice guidelines.
Inclusion criteria and patient selection. Patients of
either sex with severe claudication or limb-threatening
ischemia (stage IIb, III, or IV, Society for Vascular Sur-
gery/International Society for Cardiovascular Surgery clas-
sification) and who had stenosis or occlusion of the super-
ficial femoral artery, as demonstrated on a pretreatment
angiogram, were eligible. Inclusion criteria included inflow
vessels free of significant lesion; single superficial femoral
artery lesion located between 1 cm from the origin of the
superficial artery and 5 cm proximal to the projection of the
knee joint on anteroposterior angiographic views; lesion
length between 1 and 7 cm; and sufficient outflow, with at
least one patent leg artery. Exclusion criteria included
pregnancy, acute ischemia, previous endovascular or open
surgery in the treated superficial femoral or popliteal artery,
allergy to iodine, hemorrhagic diathesis, hypercoagulation,
and enrollment in an ongoing trial. In each patient only one
leg was included in the trial.
Preoperative evaluation. Preoperative evaluation in-
cluded analysis of symptoms; clinical examination; duplex
scanning to assess the entire lower limb arterial system, with
ankle/brachial index (ABI) measurement; and angiogra-
phy including anteroposterior and lateral views.
Pre-operative risks factors also were recorded.
Randomization process. Patients were selected on
the basis of the inclusion and exclusion criteria. Once they
agreed to participate in the study, they were recorded on a
pre-randomization list. On the day of the procedure, eligi-
ble patients were randomized from the operating room
after the guide wire successfully crossed the lesion.
The randomization process was centralized at the De-
partment of Pharmacology Clinique, Lyon, France. Pre-
randomization was carried out with dedicated software by
fax or telephone call at least 24 hours before randomiza-
tion. During the operation, randomization was made by
phone call.
Surgical technique. Lesions were approached
through an ipsilateral femoral puncture. With angiographic
guidance, a 0.035 inch Terumo (Louvain, Belgium) guide
wire was passed through the lesion. A balloon dilating
catheter was placed in the lesion and inflated to 8 to 12 atm.
Noncompliant balloon catheters, ultra-thin (Meditech;
Boston Scientific, Boston, Mass) were used in 82% of
patients, and Olbert balloon catheters (Cordis Johnson &
Johnson) were used in 18% of patients. One-half milligram
per kilogram of body weight of standard heparin was ad-
ministered before dilatation. In the group of patients ran-
domized to undergo balloon angioplasty, if results were
suboptimal as demonstrated on the control angiogram, ie,
residual stenosis greater than 30% or dissection, the balloon
was inflated one more time in an attempt to model the
lesions. According to the results, the physician had the
choice of retracting the balloon catheter without any fur-
ther intervention or of placing a stent. In the group of
patients allocated to undergo primary stenting, the stent
was placed either before or after dilation of the lesion. Only
balloon expandable Palmaz stents (Cordis or Johnson &
Johnson interventional systems) of various sizes were used
in the study. Two stents were placed in lesions larger than 5
cm.
At the end of the procedure angiograms including
views of the treated site and of the popliteal and legs arteries
were obtained. Postoperatively, patients were given low
molecular weight heparin for 24 hours, then aspirin (300
mg/d) or ticlopidine indefinitely.
Follow-up. Follow-up included symptom assessment,
clinical examination, duplex scanning of the treated sites
and run-off, and ABI measurement. Follow-up examina-
tions were performed before hospital discharge; at 1, 3, 6,
12, 18, and 24 months; and yearly thereafter for 4 years.
Repeat angiography was performed at 1-year follow-
up, or sooner if the patient experienced clinical impairment
or abnormalities were seen on follow-up duplex scans.
All clinical events were recorded for the duration of the
study.
End points. The primary end point was the presence
of more than 50% stenosis at 1-year postoperative angiog-
raphy.
Secondary end points were survival; occurrence of clin-
ical disorders including cardiac events, transcient ischemic
attack (stroke), deep venous thrombosis or pulmonary
embolism, pulmonary or renal complications, and miscel-
laneous life-threatening complications; occurrence, ac-
cording to time of follow-up, of vascular events in the
treated leg including acute ischemia, clinical stage worsen-
ing, trash foot, and need for another vascular procedure or
major amputation; and number of failed procedures at 1
year, defined as more than 50% restenosis or death.
Validation of end points and clinical events. Preop-
erative and postoperative angiograms were reviewed sepa-
rately by two independent vascular radiologists who did not
participate in the study. They were provided with a CD-
ROM which contained all preoperative and 1-year angio-
grams. Degree of stenosis was calculated with automated
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measurement software. When there was disagreement of
more than 30% between the two reviewers, films were
reviewed by a third independent reviewer, whose judgment
prevailed.
Clinical events, both general and local vascular, were
reviewed by an independent committee composed of vas-
cular surgeons, vascular specialists, and cardiologists.
Statistical analysis. Statistical analysis was performed
at EA 643 University of Lyon, France.
Analysis was done on an intent-to-treat basis
Statistical analysis was performed with the 2 test,
Fisher exact test, t test, and log-rank test, with SAS 7
software.
RESULTS
In 24 of 251 eligible patients, the guide wire could not
be placed through the lesion. Thus 227 patients were
enrolled in the study, 112 allocated to the angioplasty
selective stenting group and 115 allocated to the systematic
stenting group.
Compliance with the study protocol and follow-up was
relatively good, with only 9.6% of information sheets miss-
ing (5642 collected, 6241 expected).
Demographics. The angioplasty group included 66
(59%) men, and the angioplasty plus stent group included
and 76 (66%) men (P .265), with mean age 66.42 11.7
years and 66.54  11.15 years, respectively (P  .937). In
the angioplasty group, 89 patients (79%) had claudication,
7 patients (6.25%) had rest pain, and 16 patients (14.29%)
had gangrene or ulcer, compared with 91 patients (79%)
with claudication, 7 patients (6.09%) with rest pain, and 17
patients (14.78%) with gangrene or ulcer in the angioplasty
plus stent group. ABI at rest was 0.72  0.22 (SD) and
0.74.  0.20 (P  .519), and after exercise testing was
0.48  0.18 and 0.52  0.19 (P  .82). Mean lesion
length in the two groups, respectively, was 25.11  17.8
mm (range, 20-70 mm) and 25.36 18 mm (range, 30-70
mm) (P  .91).
Patient risk factors are given in Table I, and lesion
characteristics are given in Table II. There were no statisti-
cal differences between the two groups.
Operative procedure. An ipsilateral common femoral
approach was used in all cases. The mean length of the
balloon was 3.75  1.5 cm and 3.82  1.6 cm (P  .7),
with a mean diameter of 5.47 0.76 mm and 5.37 0.74
mm (P  0.3).
In the stent group, one stent was used in 92 patients
(80%) and two stents in 23 patients (20%). Palmaz stents
P394 were placed in 56 patients (48%), P294 in 30 (26%),
P204 in 42 (34%), and P154 in 3 (3%).
In 59 patients (52%) in the PTA group versus 28
patients (24%) in the stent group, the balloon was reinflated
(P  .001) to obtain a better morphologic aspect on the
control angiogram.
In the PTA group, 15 patients (13%) required stent
placement because of unsatisfactory results after angio-
plasty alone. One patient (0.8%) with 40% residual stenosis
did not receive a stent.
Perioperative complications in the two groups oc-
curred, respectively, in 5 patients (4.9%) and 10 patients
(8.6%) (P  0.2) and included thrombosis (2 patients
[1.7%] vs 2 patients [1.7%]), embolism (2 patients [1.7%]
vs 5 patients [4%]), arterial rupture (1 patient [0.9%] vs 0
patients), and introducer site problems, defined as difficulty
in puncturing the artery or in placing the introducer sheath
or guide wire (0 patients vs 3 patients [2.6%]).
Additional procedures performed to treat complica-
tions are listed in Table III. There were no statistically
significant differences between the two groups (P 
0.341).
Within the first postoperative month, there were no
deaths, but one general complication in each group. Minor
complications at the puncture site were noted in 7 patients
in each group (6.3% vs 6.1%). One patient in the PTA
group and 4 in the stent group required blood transfusion
(P  0.2). One patient in the angioplasty only group
Table I. Demographic data
Risk factors
Angioplasty
alone
Angioplasty
 stent
n % n %
Heart disease 29 26 30 26
Previous stroke 10 9 6 7
Hypertension 57 51 61 53
Diabetes 16 14 11 10
Dyslipidemia 48 44 43 38
Smoking 69 60 79 59
Previous vascular surgery
(contralateral limb,
aortoiliac segment,
carotid artery)
36 32 24 20
Table II. Pretreatment arteriographic data
Lesion characteristics
Angioplasty
alone
(m  6)
Angioplasty 
stent
(m  3)
n %* n %*
Location
SFA proximal 10 9 9 8
Mid-SFA 42 38 46 41
SFA distal 40 36 41 37
Popliteal artery 17 16 13 12
Lesion type
Stenosis 91 80 86 80
Occlusion 21 20 29 20
Calcifications 41 42 51 46
Patent distal artery
Popliteal 106 97 112 100
Tibio-peroneal trunk 102 93 103 94
Anterior tibial 77 71 80 72
Posterior tibial 66 62 74 67
Peroneal 88 81 89 81
SFA, Superficial femoral artery.
*Percent calculated excluding missing information.
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required a major amputation, compared with no patients in
the stent group. There were 5 minor amputations in the
angioplasty group (4%) and 2 in the stent group (1.7%)
(P  .73), all in patients with gangrene.
Pre-discharge duplex scanning was performed in 103
patients (94%) and 104 patients (93%), respectively. Mean
ABI at rest was 0.96  16 and 96  17 (P  0.88); after
exercise it was 0.83 23 and 0.88 23 after exercise (P
.40). The difference was not statistically significant com-
pared with preoperative assessment (P  0.2). Respective
duplex scanning results improved in 91% and 88% of pa-
tients, remained stable in 6.5% and 8.8%, and worsened in
2% and 3%.
Mean duration of hospitalization was 4.99  5.48 and
5.84  7.9 days (P  .41).
Respectively, 92.8% and 88.7% of patients returned
directly to home, 4.5% and 7.8% went to a convalescent
home, and 2.7% and 3.48% were referred to another hos-
pital (P  .51).
Main end point. At 1 year, 81 patients (80%) in the
angioplasty only group and 83 patients (75.5%) in the
angioplasty plus stent group had, respectively, 65 and 75
angiograms available for evaluation. Table IV shows the
distribution of lesions as determined by the imaging com-
mittee. Twenty-one procedures (32%) in the PTA group
and 26 (34%) in the stent group fulfilled the criteria for
failure (P  .85). Total occlusion of the treated site was
noted in 7 patients (10.77%) and 12 patients (16%), respec-
tively (P  0.3). The differences were not statistically
different. In 23 patients without angiograms, a duplex scan
was available at 1 year. Two of 13 patients in the PTA group
and 1 of 10 patients in the stent group had more than 50%
stenosis of the treated artery.
Secondary end points. The number of failed proce-
dures at 1 year (death or50% stenosis) was 29 of 86 (33%)
and 30 of 89 (34%), respectively (P  .9).
Median follow-up was 2.43 years (SE .08), ranging
from 8 days to 4 years.
Cumulative survival rate is shown in Fig 1. Twenty-nine
patients died during follow-up, 16 (114%) in the PTA
group and 13 (11%) in the stent group.
The number and distribution of critical clinical events
in both groups are shown in Table V. Cumulative survival
rate free of vascular events is shown in Fig 2. There were
more events in the PTA plus stent group (P  .017).
The list and frequency of vascular events during the
entire follow-up period are shown in Table VI. The differ-
ence was not statistically significant (P  .001).
DISCUSSION
This prospective multicenter study demonstrates that
systematic stenting with a Palmaz stent is not justified after
balloon angioplasty to treat relatively short superficial fem-
oral artery lesions. One-year control angiograms and clini-
cal findings over 4-year follow-up failed to show any advan-
tage to stenting. Worse, there were significantly more local
vascular events in the stent group as assessed either by total
number of events or with life table analysis.
These results confirm the conclusions of three similar
studies.15-17 A study from Sweden17 included 34 patients
with femoral occlusion. Only 20 patients were available at
1-year follow-up for angiographic evaluation. There was a
trend toward better clinical improvement and rise in ABI at
1 year in the stent group, but without reaching statistical
significance. At angiography, recurrent occlusion was seen
in 75% of patients in the PTA group and 33% in the stent
group (P .17), whereas the rate of recurrent stenosis was
significantly higher in the stent group (50% vs 25%) (P 
.033).
A study from The Netherlands16 included 51 patients
with occlusion or stenosis of the superficial femoral artery.
Follow-up included only clinical examination and duplex
scanning. Results were not statistically different. With life-
table analysis the cumulative rate of clinical and hemody-
namic success after 1 year was 85% in the angioplasty group
and 74% in the stent group (not significant). Primary
patency at 1 year, assessed with color-flow duplex ultra-
sound scanning, was 74% in the angioplasty group and 62%
in the stent group (not significant).
A study from Germany15 reported 141 patients with
short stenosis or occlusion of the femoropopliteal segment.
Follow-up included clinical assessment, ABI measurement,
and color duplex ultrasound scanning or angiography at 6
or 12 months. Follow-up angiograms obtained at 12 to 36
months were available for 46 limbs (29.9%). Again no
differences were found. Hemodynamic and clinical success
at 1 and 2 years in the PTA group was 72% and 65%,
respectively, versus 77% and 65% in the stent group (not
significant). Cumulative 1-year and 2-year angiographic
Table III. Complementary procedures
Angioplasty
alone
Angioplasty
 stent
P*n % n %
Additional stent 15 13 0 0 .001
Thrombo-aspiration 2 1.7 3 2.6 .14
Fibrinolysis 1 0.8 2 1.7 .13
Fogarthy 1 0.8 1 0.8 .2
Bypass grafting 1 0.8 4 3.4 .01
*P  .341.
Table IV. Distribution and grade of superficial femoral
artery lesions at 1-year follow-up angiography
Stenosis (%)
PTA PTA  stent
n % n %
30 38 58 38 51
31-50 6 9 11 14
51-70 8 12 4 5
71-100 6 9 10 13
Occlusion 7 11 12 16
PTA, Percutaneous transluminal angioplasty.
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primary patency rates were 63% and 53%, respectively, for
both groups.
The results of the four studies are quite consistent. The
current study had several original features. The methods
were in agreement with modern standards for such a study,
ie, centralized randomization and treatment of data, inde-
pendent assessment of end points, and relatively large num-
ber of enrolled patients, which enabled valid statistical
analysis. We targeted specific lesions, stenosis or occlusion
less than 7 cm, with good inflow and acceptable outflow
rates. In addition, we tried to eliminate as many technical
failures as possible; randomization occurred only if the
guide wire crossed the lesion. These strict criteria were used
to test the role of stenting and to prevent bias due to other
causes of poor outcome, as discussed above. The main end
point was angiography at 1 year, with review by three
independent vascular radiologists. Clinical follow-up was
extended to 4 years. The weaknesses of the study were the
great variability in the number of patients enrolled in each
center, ranging between 1 and 50 patients. Also, only 140
arteriograms (61%) were available at 1 year. The compli-
ance rate for a new angiogram is in the range noted in the
Swedish study but much higher than that in the German
study. This underlines the difficulty of obtaining angio-
grams in patients who have few or no complaints.
While successful in the early stage, systematic stent
application failed to improve overall patency. The causes of
failure of stenting in the femoropopliteal segment are cur-
rently well-known. Acute postoperative stent occlusion oc-
curred relatively infrequently in the current series, observed
in 3.13% of our patients, which is in the range noted in
previously reported series.12,16,18,19 Intra-stent hyperplasia
was responsible for most late failure. Occurrence peaked
within the first 18 months, but over the longer term results
remained stable. In addition to patency seen on the angio-
gram at 1 year, clinically significant events occurred more
Fig 1. Comparison of balloon angioplasty and stenting in superficial femoral artery. Cumulative survival.
Table V. Critical clinical events during study*
Angioplasty
alone
Angioplasty
 stent
Cardiac events 9 6
TIA/stroke 1 1
DVT/PE 2 1
Pulmonary complications 0 2
Renal insufficiency 1 0
Hemorrhage 3 0
Cancer 3 5
Infection 1 1
Contralateral vascular events 27 34
Total 47 50
TIA, Transient ischemic attack; DVT, deep vein thrombosis; PE, pulmonary
embolism.
*Ninety-seven events occurred in 67 patients.
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frequently in the stent group than in the PTA group. This
raises concern that stenting may worsen the lesion after
endovascular treatment in superficial femoral artery. This
observation is only applicable to the Palmaz stents used in
this series. Although there are no firm data, results may be
different with different stent material (steel vs nitinol) and
stent design (autoexpandable vs self-expandable).
It is not clear whether our observations are applicable
to different arterial segments.
The Dutch trial19 comparing systematic and selective
iliac stenting failed to demonstrate a difference in patency
rate after 2 years in the two groups.
In the renal artery, no randomized study has thus far
been performed. Blum20 showed that 60 months after
systematic stent placement to treat ostial stenosis, 84% of
patients were free of primary occlusion. Recurrent stenosis
of more than 50% of the vessel diameter occurred in 8 of 74
arteries (11%). Repeat intervention resulted in a secondary
patency rate of 92%.
In the carotid segment, we reported 7% intra-stent
hyperplasia after angioplasty and stenting.21 Conversely,
two randomized studies of the coronary circulation dem-
onstrated better patency with stenting after 6 months.
Fischman et al22 reported that at 6 months patients with
stented lesions continued to have a larger luminal diame-
ter(1.74  0.60 mm vs 1.56  0.65 mm; P  .007) and a
lower rate of recurrent stenosis (31.6% vs 42.1%; P .046)
than did patients who had undergone balloon angioplasty.
In a study by Serruys et al,23 mean (SD) minimal luminal
diameter immediately after the procedure was 2.48 0.39
mm in the stent group versus 2.05  0.33 mm in the
angioplasty group; at follow-up, the diameter was 1.82 
Fig 2. Comparison of balloon angioplasty and stenting in superficial femoral artery. Cumulative survival free of
vascular critical events on the ipsilateral leg.
Table VI. Vascular local events in treated limb during
study*
Angioplasty
Angioplasty
 stent
Acute ischemia 0 3
Clinical stage worsening 37 57
Trash foot 1 4
New ipsilateral
vascular procedure
9 14
Major amputation 1 1
Total 48 79
P  .001.
*One hundred twenty-seven events occurred in 87 patients.
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0.64 mm in the stent group and 1.73  0.55 mm in the
angioplasty group (P  .09). The rate of more than 50%
recurrent stenosis was 22% and 32% percent, respectively
(P  .02). An update of the Benestent-I trial24 demon-
strated that the early benefit of stenting was durable. At 5
years, in the PTA group 27.3% of patients had undergone
target lesion revascularization, compared with 17.2% of
patients in the stent group (P .008). However, event-free
survival rate (59.8% vs 65.6%; P  .20) between the stent
and PTA groups no longer achieved statistical significance.
It is still uncertain whether the better results in the
coronary circulation as opposed to the femoral and iliac
arteries are due to differences in the healing process, artery
texture, flow velocity, resistance to flow, size of stent, drug
regimen, or the method of follow-up.
Will recent developments in stent technology improve
the results of superficial femoral artery stenting? Trials are
under way to test the role of adjuvant drugs, gene therapy,
and brachytherapy to reduce intra-stent hyperplasia. Bene-
ficial effects of coated stents have been shown in the coro-
nary circulation over the short term, but evidence is lacking
insofar as long-term results and non-coronary arteries are
concerned. Alternative endovascular treatments such as
subintimal angioplasty25,26 and remote endarterectomy27
also must be evaluated against the more conventional and
relatively disappointing approach of femoral stenting.
CONCLUSIONS
With current stent technology, systematic stenting of
short stenosis or occlusion of the superficial femoral artery
is not justified. Stent placement should be reserved for
patients with suboptimal results after balloon angioplasty.
Supported by grants from Cordis, Johnson & Johnson,
Lafon, Aventis, and Socie´te´ Franc¸aise de Chirurgie Vascu-
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APPENDIX. STUDY ORGANIZATION
Scientific committee
Pr J.-P. Becquemin, Pr J.-P. Favre, Dr J. Marzelle, and Dr A.
Leizorovicz
Participating centers and number of cases
Drs Age´, Drevet, and Lepine, Clinique Mutualiste, Lyon, France
(n  16)
Pr Alimi, Hoˆpital Nord, Marseille, France (n  1)
Pr Azorin, Hoˆpital Avicenne, Bobigny, France (n  6)
Pr Becquemin and Dr Desgranges, Hoˆpital Henri Mondor,
Cre´tiel, France (n  50)
Drs Bergeron and Amichot, Hoˆpital St Joseph, Marseille, France
(n  19)
Dr Cardon, Clinique les Franciscaines, Nimes, France (n  14)
Dr Chatelard, Clinique du Tonkin, Villeurbanne, France (n  4)
Pr Favre, Hoˆpital Nord, St-Etienne, France (n  17)
Pr Castellani and Dr Martinez, Hopital de Tours, France (n  9)
Pr Gouny, Hoˆpital Tenon, Paris, France (n  4)
Drs Jausseran and Ferdani, Hoˆpital St Joseph, Marseille, France
(n  1)
Drs Lermusiaux and Artru, Clinique du Pre´, Le Mans, France (n 6)
Pr Magne, Dr Voirin, and CH Michallon, Hoˆpital La Tronche,
Grenoble, France (n 7)
Dr Marcade´, Clinique du Mail, la Rochelle, France (n 5)
Drs Marzelle and Cormier, Clinique la Defense, Nanterre, France
(n 8)
Dr Mialhe, Clinique Notre Dame, Draguignan, France (n 12)
Dr Paneau, Clinique Saint Joseph, Colmar, France (n 7)
Dr Sarradon, Polyclinique les Fleurs, Ollioules, France (n 9)
Pr Prat, Dr Vasseur, and Pr Stankowiak, Centre Hospitalier Lille,
France (n 2)
Drs Tobiana and Chaircop, Centre Hospitalier Beziers, France (n 7)
Pr Watelet, Centre Hospitalier Charles Nicolles, Rouen, France
(n  12)
Dr Vrielynck, Polyclinique St Andre, Reims, France (n  1)
Dr Billon, Clinique Mutualiste St-Etienne, France (n  7)
Dr Bosiers, Alegemeen Ziekenhuis, Dendermonde, Belgium (n 3)
Imaging recording and arteriogram review
Dr Cardon, Pr Bartoli, Pr Rousseau, and Dr Kobeiter
Committee for validation of critical events
Pr Gueret, Pr Nussaume, Pr Emmerich, Dr Boissier, Dr Cron, and
Dr Helou
Data recording and treatment
Dr Leizorovisz, Dr Gauthier, Dr Gelas-Dore, Dr Cherief, and Dr
C. Cornu
Software monitoring
N Vise`le, F Lorenzilli, N Rodrigo, and M Herve´
Statistical analysis
C. Nemoz
Center monitoring
C. Lowe, C. Corsin, and S. Dufourmantelle
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